Journal of Microencapsulation · 2019 · 18 citations · 34 references
PharmacyPharmaceuticsPharmacologyBioavailabilityControlled Release FormulationsDrug DeliveryControlled Release MechanismsGlucagon-like Peptide-1 Receptor AgonistsIncretin-based TherapiesNanocarriers For TherapeuticsNanoparticle FormulationsPeptide DeliveryGlucagon-like PeptidesMicroparticle Delivery SystemsMicroparticlesParticle-size DistributionPharmacologic EquivalencePolymeric MicroparticlesSubcutaneous Drug AdministrationSustained Release Kinetics
The GLP1-receptor agonists exert regulatory key roles in diabetes, obesity and related complications. Here we aimed to develop polymeric microparticles loaded with homologous human GLP1 (7-37) or the analogue liraglutide. Peptide-loaded microparticles were prepared by a double emulsion and solvent evaporation process with a set of eight polymers based on lactide (PLA) or lactide-glycolide (PLGA), and evaluated for particle-size distribution, morphology, in vitro release and pharmacologic activity in mice. The resulting microparticles showed size distribution of about 30–50 μm. The in vitro kinetic release assays showed a sustained release of the peptides extending up to 30–40 days. In vivo evaluation in Swiss male mice revealed a similar extension of glycemic and body weight gain modulation for up to 25 days after a single subcutaneous administration of either hGLP1-microparticles or liraglutide-microparticles. Microparticles-loaded hGLP1 shows equivalent in vivo pharmacologic activity to the microparticles-loaded liraglutide.
34
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso, Gilbert H. Daniels, Kirstine Brown‐Frandsen et al. · New England Journal of Medicine · 2016 · 7.3K citations · Full text
The American Journal of Physiology
The American Naturalist · 1899 · 5.7K citations
A role for glucagon-like peptide-1 in the central regulation of feeding
Mandy D. Turton, Donal O’Shea, I. Gunn et al. · Nature · 1996 · 1.9K citations